Daily Bio News Summary — 2026-09-22

Tuesday’s harvest produced twenty-five items across seven sources — the largest single-day batch the collection has recorded since the radiopharma-heavy Monday that opened the week. After four consecutive sweeps of the same eleven homepages had returned only a handful of genuinely new stories each day, the feed turned over: seven clinical readouts, six FDA or regulatory actions, three financing and deal items, one large workforce disclosure, and a leadership transition.

The composition is broad rather than concentrated. There is no single billion-dollar merger to anchor the day; instead the batch is carried by a regulatory first in a rare neurological disease, a cluster of mid- and late-stage readouts spanning immunology, nephrology, neurology and psychiatry, and a metabolic-medicine thread that runs from Roche’s in-licensed obesity asset through Novo’s capital markets week.

An FDA first in ataxia-telangiectasia

The day’s most consequential regulatory action is IntraBio’s expansion of AQNEURSA (levacetylleucine) to ataxia-telangiectasia (Fierce Pharma, 2026-09-21). According to the source, this is the first treatment indicated for A-T anywhere in the world, and a second approved indication for the chemically altered amino acid after Niemann-Pick disease type C. Fierce frames the approval as resting on phase 3 data from a crossover study, and characterises the company as “on a roll” with its expansion plans for the molecule.

The rest of the regulatory set is narrower in scope but unusually diverse in geography and modality. SystImmune received FDA clearance of an IND for SI-B037, a bispecific antibody (PR Newswire FDA, 2026-09-22) — the company describes this as its first IND built on New Approach Methodologies, a detail that matters more for how the filing was assembled than for the target itself. Kedrion Biopharma picked up Orphan Drug Designation for QIVIGY in stiff person syndrome (PR Newswire FDA, 2026-09-22), and Mercy BioAnalytics said the FDA has accepted the start of a prospective pivotal study of its Evident ovarian cancer screening test (PR Newswire FDA, 2026-09-21). Myrava cleared a 510(k) for a patient-specific 3D-printed bolus device for radiation therapy (PR Newswire FDA, 2026-09-22), and Rise Therapeutics completed dose escalation in the phase 1 cancer trial of its oral immunotherapy R-5780 (PR Newswire FDA, 2026-09-22). Kazia Therapeutics reported that a partner dosed the first patient in a phase 1b/2a study of paxalisib in rare seizure disorders (PR Newswire FDA, 2026-09-22).

Sun Pharma, meanwhile, welcomed the publication of the first standardised U.S. treatment recommendations for adults with severe alopecia areata (PR Newswire FDA, 2026-09-22) — a guideline milestone rather than an approval, but one the company chose to announce through the FDA-focused wire.

A dense clinical readout cluster

Amgen reported a phase 3 win for dazodalibep in Sjögren’s disease (Fierce Biotech, 2026-09-22). The headline frames it as a positive sign for the Horizon Therapeutics-acquired pipeline, which has otherwise struggled to gain traction. Vertex followed with positive phase 2b data for inaxaplin in APOL1-mediated kidney disease, work the source describes as boosting the company’s effort to move beyond the population its pivotal trial targets (Fierce Biotech, 2026-09-22).

In neurology, Otsuka and Ionis said their partnered ALS candidate hit the primary endpoint of a phase 3 study, positioning the partners to talk to regulators about expedited approval paths (Fierce Biotech, 2026-09-22). In psychiatry, Johnson & Johnson reported a phase 3 win for Caplyta in one of two bipolar manic-episode studies, framing it as a wider indication on top of the drug’s existing use (Fierce Pharma, 2026-09-21).

The metabolic thread is the most revealing. Roche said enicepatide — the shot it acquired with Carmot — hit weight and blood-sugar goals in a phase 2 diabetes trial, with the headline figure being 15.5% weight loss at the top dose (Endpoints News, 2026-09-22). Novo released low-dose CagriSema data timed to its capital markets day, described as competitive, as an approval decision on the drug approaches (Endpoints News, 2026-09-22). Set beside the Vertex and Amgen readouts, the day’s clinical news skews toward large-population, commercially contested indications rather than the single-asset rare-disease readouts that dominated earlier in the month.

Dealmaking and filings return

Lexeo Therapeutics agreed to acquire Mantle Therapeutics for $8.3 million upfront, adding Friedreich ataxia assets — four in total, led by the clinical-stage oral combination LX3010 (Fierce Biotech, 2026-09-22). The headline frames the deal as portfolio expansion plus three strategic collaborations, with up to $13 million in additional milestones.

Boehringer Ingelheim bet up to $1 billion on an AI-centred solid tumour collaboration with Envisagenics, whose platform screens for cancer-specific RNA alterations the companies want to reach with modalities including multi-specific antibodies, ADCs and T cell engagers (BioSpace, 2026-09-22). Separately, Iambic Therapeutics filed to go public and said it could move IAM1363, its HER2-directed lead, into a registrational trial as early as next year (Endpoints News, 2026-09-22).

Supply-side and geographic themes round out the group. BioSpace reported a forecast that Western licensing deals for Chinese radioligand therapies will jump in 2027 (BioSpace, 2026-09-22), noting that such deals have been rare so far and the pool of capable Western buyers is limited. On the manufacturing side, Altruist Biologics — a wholly owned subsidiary of Innovent Biologics — said its Suzhou site received EMA GMP certification enabling commercial supply into Europe (PR Newswire FDA, 2026-09-22).

Novo’s week: fewer people, more data

Novo’s workforce has shrunk by roughly 13,000 people over the past year, with CEO Maziar Mike Doustdar disclosing an additional 4,000 departures that a spokesperson linked to attrition and other measures (BioSpace, 2026-09-22). The article ties the reduction to the company’s effort to unify and drive more funding into R&D. Read next to the CagriSema data and the ongoing capital markets meetings, the disclosure is the clearest signal in today’s batch that the largest metabolic players are reallocating rather than simply growing.

Travere Therapeutics supplied the day’s leadership news: CEO Eric Dube will step down after roughly eight years, with Bradley Campbell — until recently the head of Amicus Therapeutics — taking over on December 1, 2026, while Dube stays on as an executive advisor into February (Fierce Pharma, 2026-09-22).

What this batch is NOT telling us

No large pharmaceutical merger. No priced IPO — Iambic filed, but nothing debuted. No gene-therapy readout in a rare disease despite the Lexeo acquisition news, and no oncology registrational data. No China-originated cross-border licensing deal was signed; the radioligand item is a forecast, not a transaction. And no drug-pricing or healthcare-policy items appear: the harvest’s standing filters exclude opinion pieces and politically charged policy coverage, which on a week with active price-deal news removes a category of story that trade outlets are covering heavily.

Reading order

1. IntraBio / AQNEURSA in ataxia-telangiectasia — the day’s only genuine “first in the world” claim.
2. Amgen’s dazodalibep phase 3 — the largest-population immunology readout in the batch.
3. Roche’s enicepatide phase 2 — the clearest competitive signal in obesity/diabetes this week.
4. Boehringer-Ingelheim / Envisagenics — up to $1 billion for an RNA-splicing AI platform.
5. Novo’s 13,000-person reduction — the structural story behind the metabolic headlines.

How to read the underlying articles

Each item above is backed by a markdown file in src/content/news/ whose frontmatter carries the title, description, pubDate, sourceUrl and sourceName used in this synthesis. Every specific figure quoted here — deal values, percentages, staff counts, effective dates — comes from that frontmatter and should be checked against the source article before being reused.

Today’s items

1. IntraBio’s Aqneursa scores FDA approval for rare ataxia — Fierce Pharma, 2026-09-21
2. Amgen fusion protein eases Sjögren’s severity in ph. 3 win — Fierce Biotech, 2026-09-22
3. Vertex’s midstage data amplify kidney disease market opportunity — Fierce Biotech, 2026-09-22
4. Otsuka heads to FDA as Ionis-allied ALS drug hits primary goal — Fierce Biotech, 2026-09-22
5. J&J touts Caplyta win in 1 of 2 bipolar manic episode studies — Fierce Pharma, 2026-09-21
6. Lexeo acquires Mantle for $8M, adding Friedreich ataxia assets — Fierce Biotech, 2026-09-22
7. Travere CEO Eric Dube to step down — Fierce Pharma, 2026-09-22
8. Roche says Carmot-acquired shot delivers Phase 2 win in overweight patients with diabetes — Endpoints News, 2026-09-22
9. Novo offers low-dose CagriSema data as approval decision looms — Endpoints News, 2026-09-22
10. Nvidia-backed Iambic files for IPO, disclosing new clinic and dealmaking details — Endpoints News, 2026-09-22
11. Boehringer Ingelheim bets up to $1B in AI-centered solid tumor collab with Envisagenics — BioSpace, 2026-09-22
12. Western licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecasts — BioSpace, 2026-09-22
13. Novo’s workforce reduction climbs to 13,000 to fuel R&D work — BioSpace, 2026-09-22
14. Addiction clinics see rising cases of kratom and 7-OH withdrawal — STAT News, 2026-09-21
15. SystImmune receives FDA clearance of IND application for bispecific antibody SI-B037 — PR Newswire FDA, 2026-09-22
16. FDA grants orphan drug designation to Kedrion’s QIVIGY for stiff person syndrome — PR Newswire FDA, 2026-09-22
17. Mercy BioAnalytics receives FDA approval to initiate prospective pivotal study of Evident ovarian cancer screening test — PR Newswire FDA, 2026-09-21
18. Myrava advances personalized radiation therapy with FDA 510(k) clearance — PR Newswire FDA, 2026-09-22
19. Rise Therapeutics completes dose escalation in R-5780 phase 1 cancer trial — PR Newswire FDA, 2026-09-22
20. Kazia Therapeutics announces Sovargen doses first patient in phase 1b/2a trial of paxalisib — PR Newswire FDA, 2026-09-22
21. Altruist Biologics’ Suzhou site receives EMA GMP certification — PR Newswire FDA, 2026-09-22
22. First-ever standardized U.S. treatment recommendations issued for adults with severe alopecia areata — PR Newswire FDA, 2026-09-22
23. Decoy Therapeutics exploring pan-filovirus program via FDA Animal Rule pathway — PR Newswire FDA, 2026-09-22
24. Hedia secures regulatory approval to expand digital diabetes care to pediatric patients — PR Newswire FDA, 2026-09-22
25. AIMD expands A-LRYNGO, the world’s first AI-guided video laryngoscope, to global markets — PR Newswire FDA, 2026-09-22